1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market

  • March 2014
  • 68 pages
  • Frost & Sullivan
Report ID: 2051530

Summary

Table of Contents

Imminent Arrival of 3 Promising Drug Classes Intensifies Competition

Executive Summary

•The market for moderate-to-severe psoriasis therapeutics is becoming increasingly competitive with the imminent arrival of a new class of biologic: anti-interleukin–17(IL-17). If approved, Novartis will lead the pack with a potential 2014 launch of first-in-class secukinumab, followed by Eli Lilly’s izekizumab and Amgen/AstraZeneca’s brodalumab.
•The market also looks to benefit from the arrival of xxnovel oral drugs: Pfizer’s Xeljanz, a janus kinase (JAK) inhibitor approved for rheumatoid arthritis (RA) in the United States, and Celgene’s Apremilast, a phosphodiesterase-4 (PDE4) inhibitor.
•The development pipeline for moderate-to-severe psoriasis therapeutics is competitive, with at leastxx investigational biologic and small molecule drugs in various stages of development. Particularly competitive classes include anti-IL-17 with xx candidates in late stage development and anti-interleukin-23 (IL-23) with 5 candidates in various stages of development.
oThere are also xxbiosimilar anti-tumor necrosis factor (TNF) agents in Phase xx trials for psoriasis— biosimilar versions of adalimumab and 1 biosimilar etanercept.
•The pipeline for mild-to-moderate psoriasis includes at least xxinvestigational topical therapies in various stages of development.
•Pivotal clinical trial programs for 6 late-stage candidates comprise xx to xx trials each and include approximatelyxx to xxpatients in total. Most include at least 1 study design that evaluates the effects of treatment withdrawal and retreatment, which is a common practice with psoriasis patients.
•Comparative head-to-head trials have also become a common practice, with most sponsors of late-stage candidates pitting their drugs against Enbrel (etanercept) or Stelara (ustekimumab) in the case of brodalumab. Novartis was the first to show superiority of an anti-IL-17 over an anti-TNF (Enbrel) in a Phasexx trial with recently announced results of FIXTURE.

Methodology and Scope

•This research service focuses on prescription drugs used for the treatment of mild-to-moderate and moderate-to-severe chronic plaque psoriasis (PS). This study does not cover non-pharmaceutical therapies such as phototherapy or treatments for related disorders such as psoriatic arthritis (PsA).
•A product and pipeline assessment is provided for marketed and investigational products for the treatment of chronic PS. Segmentation by disease severity and drug class is provided, along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
•The information contained in this research service was derived from published sources, including the following: disease organization Web sites; public health organization Web sites; company publications, including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.

Introduction

Psoriasis is a chronic inflammatory disease of varying severity that manifests primarily as inflammation of the skin in the form of scaling, erythematous, disfiguring plaques that may be associated with pain, itching, and significant quality of life issues. Despite localization of the main symptom to the skin, psoriasis is a systemic autoimmune inflammatory disease. It is often associated with co-morbidities such as PsA, inflammatory bowel diseases, cardiovascular disease, diabetes, and lymphoma; severe cases may increase overall mortality risk. There is currently no cure for psoriasis. The goal of treatment is to reduce the severity and coverage of lesions and to induce and maintain remission for as long as possible.

The market for psoriasis treatments is mainly focused on developing improved therapeutic options for moderate-to-severe cases of psoriasis where there is still a great deal of unmet need. Since the introduction of biologic therapies such as TNF inhibitors for psoriasis and related autoimmune diseases such as RA, treatment of these diseases has greatly improved because of the strong efficacy of these revolutionary therapies. However, available biologics are associated with varying or waning efficacy, along with significant safety issues such as infections.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Ulcerative Colitis Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost laye ...

Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The global human microbiome market is estimated to reach USD 899.1 million by 2025, growing at a CAGR of 21.1% during the forecast period (2022–2025) Factors such as increased focus on human microbiome ...

Epiomic Epidemiology Series: Ankylosing Spondylitis Forecast in 13 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • March 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Ankylosing Spondylitis in 13 Major Markets Ankylosing Spondylitis (AkS) is a chronic, systemic inflammatory autoimmune disease. It ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • June 2017
    9 pages
  • Cancer  

    Pathology  

  • United States  

View report >

Infectious Disease Statistics

  • June 2017
    172 pages
  • Infectious Dise...  

    Hospital  

  • United States  

    Asia  

    North America  

View report >

Cardiovascular Disease Statistics and Obesity Statistics in the US

  • June 2017
    30 pages
  • Cardiovascular ...  

    Obesity  

    Therapy  

  • United States  

View report >

Related Market Segments :

Autoimmune Disease
Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.